L. Morales

发表

Prospective assessment of the endometrium in postmenopausal breast cancer patients treated with fulvestrant

D. Timmerman, P. Neven, R. Paridaens, 2009, Breast Cancer Research and Treatment.

Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients.

D. Timmerman, P. Neven, S. Van Huffel, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.

E. Rutgers, R. Paridaens, J. Bogaerts, 2007, European journal of cancer.

Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data.

B. van Calster, D. Timmerman, P. Neven, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients

E. van Limbergen, D. Timmerman, P. Neven, 2004, Anti-cancer drugs.

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.

Y. Wang, A. Schneeweiss, Ming Yan, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome.

B. van Calster, D. Timmerman, P. Neven, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer. First results of a randomized phase III trial EORTC 10901

E. Rutgers, R. Paridaens, P. Therasse, 2004 .

Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging

D. Timmerman, P. Neven, R. Paridaens, 2007, Breast Cancer Research and Treatment.

Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer

A. Schneeweiss, M. Parmar, J. Mackey, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Endometrial safety of third generation aromatase inhibitors versus tamoxifen in breast cancer patients.

D. Timmerman, P. Neven, R. Paridaens, 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.

B. van Calster, D. Timmerman, P. Neven, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)

A. Schneeweiss, K. Russell, F. André, 2020 .

Prospective study of uterine sonographic changes after 3 months endocrine treatment in postmenopausal breast cancer patients: tamoxifen is estrogenic while aromatase inhibitors induce atrophy and can reverse the effect of tamoxifen

S. Huffel, D. Timmerman, P. Neven, 2003 .

Menopausal symptoms and uterine changes in postmenopausal breast cancer patients receiving tamoxifen or third generation aromatase inhibitors

S. Huffel, D. Timmerman, P. Neven, 2004 .

Prospective study on the effect of endocrine treatments on menopausal symptoms in breast cancer patients

S. Huffel, D. Timmerman, P. Neven, 2003 .

Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting

P. Neven, R. Paridaens, L. Morales, 2005, Current opinion in oncology.

Aromatase Inhibitors and Postmenopausal Breast Cancer Patients with Tamoxifen-Induced Endometrial Pathology

D. Timmerman, P. Neven, R. Paridaens, 2006, Clinical Cancer Research.